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Abstract
Hereditaryangioedema (HAE)is alifelong illness characterized byrecurrent swelling of
the skin, intestinal tract, and, ominously, the upper airway. It is caused by inadequate
activity of the protein C1-inhibitor, with dysfunction in the kallikrein/bradykinin
pathway underlying the clinical symptoms. In addition to the physical symptoms,
patients experience signiﬁcant decrements in vocational and school achievement as well
as in overall quality of life. Symptoms often begin in childhood and occur by age 20 in
most patients, but life-threatening attacks are uncommon in the pediatric population.
The availability of new therapies has transformed the management of HAE.
Hereditary angioedema (HAE) was ﬁrst described in the 1880s
by Quincke (1) and Osler (2). Patients with HAE experience
recurrent, unpredictable attacks of edema primarily affecting
the skin, intestinal tract, and upper airway (3). Attacks
typically develop and resolve slowly, lasting 2–5 days. Signif-
icant variability in disease severity is seen, with rare individuals
carrying causative mutations but remaining asymptomatic, and
other patients experiencing frequent severe attacks (4). The
recent approval of safe, effective targeted therapies has
revolutionized the treatment of HAE. A plethora of consensus
statements and guidelines have been recently promulgated to
guide providers in diagnosing and treating HAE, but the
evidence supporting many of the recommendations remains at
the level of expert opinion (5–9). This review focuses on the
presentation, diagnosis, and management of HAE with
decreased C1-inhibitor (C1-INH) function in children and
adolescents. Both acquired HAE and HAE with normal C1-
INH, formerly known as type III HAE, are rare in the pediatric
age group and not considered further here
HAE pathophysiology
C1-INH is a member of the serpin class of protease inhibitors,
which act as decoy substrates for proteases (10,11). Protease
inhibition by C1-INH results from covalent linkage of the
protease to the C1-INH molecule, perhaps explaining why a
single functional C1-INH gene is insufﬁcient to prevent HAE
symptoms. C1-INH is named for the ability to inhibit C1, the
ﬁrst component of the classical complement cascade, but it also
inhibits a number of other circulating enzymes including
kallikrein, activated factors XI and XII, and tissue plasmino-
gen activator (10,11).
Conclusive evidence demonstrates that the recurrent epi-
sodes of swelling in HAE are primarily due to increased
production of bradykinin secondary to increased activity of
plasma kallikrein (10–12), as shown in Fig. 1. Brieﬂy, high-
molecular-weight kininogen (HMWK), the precursor of brady-
kinin, circulates in the bloodstream bound to pre-kallikrein
(10,11). Activation of pre-kallikrein to plasma kallikrein,
usually by activated factor XII, results in generation of
bradykinin from HMWK. Bradykinin then binds to its
receptor on endothelial cells, resulting in increased vascular
permeability and the swelling typical of HAE (10,11). It is not
known why attacks are temporally and anatomically limited,
while C1-INH activity is constitutively reduced.
Type I and type II HAE both result from heterozygous
mutations in the C1-INH gene and are the result of deﬁcient
C1-INH function (13). Decreased levels of C1-INH character-
ize type I HAE, whereas in type II HAE, C1-INH levels are
normal or increased, but activity is decreased (14). Patients
with type I or type II HAE have decreased C1-INH activity,
typically about 30% of normal. This is less than would be
predicted and may be due to increased C1-INH consumption.
Patients within a kindred with identical C1-INH mutations can
have vastly different courses (4), perhaps because of the effects
of modiﬁer genes. As many as one quarter of patients with
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mutations (15).
Homozygous missense mutations in C1-INH have been
described in sis patients from three kindreds, but reported
symptoms were relatively mild and heterozygotes were asymp-
tomatic, suggesting that the mutated C1-INH alleles retain
some residual function (16–18).
Clinical presentation
Hereditary angioedema attacks are characterized by non-
pruritic, often painful swelling, with the skin, gastrointestinal
(GI) tract, and upper airway the most commonly involved
locations (19). Rarely, attacks may involve other sites including
the esophagus, brain, kidney, and pancreas (19,20). Attacks
typically progress and resolve slowly, with a total attack
duration of 2–5 days. Cutaneous attacks localized to the
extremities are the most common, but over time, most patients
have attacks at multiple locations. Some patients have symp-
toms limited to the GI tract, complicating recognition of the
disease and leading to delayed diagnosis, a problem that is
common in HAE.
Attacks are sometimes, but not consistently, preceded by a
prodromal phase (21). Patients typically report feeling a
sensation of tingling or altered sensation prior to the start of
skin swelling. Patients may also experience a rash termed
erythema marginatum, which is a non-raised, non-pruritic
erythematous eruption with central pallor. Urticaria is not
associated with HAE, but as hives are common, they may be
seen coincidentally in some patients with HAE.
A number of factors can predispose a patient to attacks,
including stress and local trauma. Estrogen is a known trigger,
and patients with HAE should avoid exposure to exogenous
estrogens (19). Angiotensin-converting enzyme (ACE) is the
primary enzyme responsible for breakdown of bradykinin,
although other peptidases also participate (11,12). ACE
inhibitors, frequently prescribed for hypertension and renal
disease, can precipitate sudden worsening or even unmask
HAE and should be avoided (22). ACE inhibitors can
occasionally trigger angioedema in patients without HAE (9),
although this is rare in children, perhaps because these drugs
are not frequently used in this population.
The distribution of attacks varies among patients. In one
large series, all patients had extremity swelling, 97% had
abdominal attacks, and just over half had laryngeal attacks
(19). On a per-attack basis, about 50% of attacks affected the
skin and just slightly less affected the abdomen (19). Upper
airway attacks are potentially fatal. A recent analysis of
patients who asphyxiated from HAE demonstrated a signiﬁ-
cantly elevated risk in those who had undiagnosed HAE,
emphasizing the need for prompt diagnosis (23). Abdominal
attacks, if not recognized as HAE, can be mistaken for a
variety of other intra-abdominal illnesses including appendici-
tis. Patients may undergo unnecessary surgical intervention
(24), although this seems less common with the widespread use
of computed tomography and ultrasound for imaging (25).
HAE in childhood
The onset of HAE symptoms is variable, but occurs in the ﬁrst
or second decade of life in most patients. An early US report
revealed nearly half of patients had symptoms by age 6,
although severity was typically mild (26). Farkas described a
series of children with HAE from Hungary and noted the ﬁrst
attack at a median age of 6.6 yrs, with a range from 4 to 11 yrs
(27). Similarly, a series from Germany showed a median ﬁrst
attack at 11 yrs but with a very broad age range (19). Patients
experienced attacks as early as the ﬁrst year of life. Importantly,
almost 90% of patients (186 of 209) had onset of symptoms
before age 20. Median age of ﬁrst HAE symptoms was 9.5 yrs
in a series from Denmark (28) and 12.5 in a series from Spain
(29). These series are primarily based on diagnosed cases and so
may miss patients with mild or asymptomatic disease, although
the Spanish series included a number of asymptomatic individ-
uals. While most patients experience symptoms during child-
hood and adolescence, a fraction remains asymptomatic
Figure 1 Pathophysiology of HAE.
Decreased C1-INH activity leads to
increased production of bradykinin.
Bradykinin binds to its receptor on
endothelial cells, increasing vascular
permeability and leading to the
characteristic symptoms of HAE.
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ing a disease-causing mutation (19,26,29). Identiﬁcation of
these asymptomatic carriers is crucial, as initial symptoms can
manifest as severe and/or life-threatening edema (23).
While symptoms may start in early childhood, attacks are
typically infrequent in prepubertal children. Early onset of
symptoms and frequent attacks in childhood predict more
severe disease in adulthood (19,28). The number and severity of
attacks typically increase in both sexes around puberty.
Although this may be due to increased levels of endogenous
estrogen in girls, the explanation for the worsening in boys is
unknown. The distribution of attacks in adolescent patients
typically mirrors that of adults. Nearly half of patients will have
an upper airway attack by age 18 (19), and life-threatening
attacks have been reported even in young children (23,30). Fatal
attacks are rare in childhood, with only 3 of 70 deaths occurring
in patients under age 21 in the largest published series (23).
Quality of life
Besides the burden ofthe disease itself, HAE causes a signiﬁcant
decrease in quality of life (QOL). Patients with HAE have
diminished physical and psychological QOL (31). Decreased
QOL is partially due to the unpredictable nature of attacks. In a
recent study of more than 450 patients, the majority reported
decreased educational and vocational achievement because of
HAE (31). Patients reported missing a median of 1.9 days of
school (or 3.3 days of work) with their most recent attack (31).
PreliminaryevidenceindicatesanimprovementinQOLwiththe
availability of effective therapy for treatment of attacks (32).
Diagnosis
The diagnoses of type I and type II HAE are dependent on
demonstration of low levels of C1-INH protein or function,
respectively. C4 is low at all times in a large majority of
patients and invariably low during attacks. Published algo-
rithms for diagnosis recommend screening with C4 initially,
followed by C1-INH level and then activity if required (5). For
patients with normal C4 but a history strongly suggestive of
HAE, C4 should be rechecked during an attack (33). In
practice, many physicians check C1-INH function initially to
either establish or exclude the diagnosis of HAE. This may be
particularly appropriate in children for whom repeated blood
draws are problematic. Traditionally, it was believed that the
level of C1-INH function did not predict disease severity;
however, a recent report demonstrated that residual C1-INH
activity was inversely correlated with disease severity (34).
However, this does not imply that monitoring C1-INH levels
should be used as part of disease management.
While development of the complement and kallikrein/
bradykinin systems have not been well studied, available data
suggest that neonates have levels below those seen in adults
(35). Therefore, testing for C1-INH function can be deferred
until 6 months and then repeated at 1 yr of age (26). Diagnosis
of HAE is often delayed, with some patients being symptom-
atic for 10 or more years before HAE is identiﬁed, particularly
when a family history of HAE is absent (36).
Management
Counseling and prevention of attacks
All patients and families should be educated about the
disease, the risk of disease in family members, and factors
that can worsen the disease or precipitate attacks (37).
Patients should be advised to continue an active lifestyle
including regular physical activity. However, as trauma is a
frequent attack trigger, some patients may need to avoid
contact sports. Estrogen-containing hormones should be
avoided for contraception and normalization of menstruation
in girls during and after puberty. Although not typically used
in childhood, patients and families should know to avoid
ACE inhibitors, as these can cause abrupt worsening of
disease. Likewise, patients and families should be aware that
dental and surgical procedures often precipitate attacks;
therefore, prophylaxis or availability of emergency treatment
should be arranged.
Emergency plan
All patients with HAE should have an emergency plan for the
treatment of attacks, a recommendation reinforced by a recent
series regarding the frequency of laryngeal attacks and
asphyxiation (23). This includes patients on long-term prophy-
laxis who may experience breakthrough attacks. For patients
with infrequent attacks, this plan may be as simple as knowing
an emergency facility nearby where effective acute therapy is
available. The provider can help facilitate availability of one or
more of the newer targeted HAE therapies in an emergency
department or similar facility close to home and school.
Likewise, working on a detailed care plan at a designated
medical facility can speed treatment, increase the comfort level
of both the patient and providers, and minimize unforeseen
problems. For patients with more frequent attacks, on-demand
treatment can be available at home or work, including
administration by the patient or caregiver if appropriate.
However, patients need to seek emergency medical care for
upper airway attacks.
Medication
Antihistamines and steroids are typically ineffective for the
bradykinin-mediated swelling of HAE, although they are often
tried, particularly in patients with undiagnosed HAE and by
providers unfamiliar with the disease. It has been suggested
that epinephrine may be successful as a temporizing measure
(38), particularly in the setting of laryngeal edema, but no
studies show efﬁcacy and it should not be relied on.
Older treatment options
For many years, there were limited options for the treatment of
HAE in the United States, while puriﬁed C1-INH (pC1-INH)
concentrate was available in Europe and other countries.
Danazol was noted to increase the production of C1-INH and
decrease the rate and severity of attacks (39). Attenuated
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adverse effects including hirsutism, acne, weight gain, and
psychological changes (40), which can be particularly prob-
lematic in women. In addition, androgens have adverse effects
on blood lipid proﬁles and may cause hepatic adenomas and
even adenocarcinoma (41).
Androgen use should be avoided in children. By causing
premature closure of the growth plate, androgens are associ-
ated with a risk of decreased stature when used in childhood.
While a small series and case reports indicated efﬁcacy and
tolerability in prepubertal children with severe HAE (42–44),
the advent of safer, targeted therapies for HAE eliminates the
need for attenuated androgens in the pediatric population.
Antiﬁbrinolytic medicines, including tranexamic acid and
epsilon-aminocaproic acid, represent an alternative for HAE
prophylaxis with a more acceptable adverse-effect proﬁle in the
pediatric age group. Initial data showed an improvement in
attack frequency and severity in adult patients with HAE (45),
but other data suggest marginal beneﬁt, and some guidelines
do not recommend use for prophylaxis (7). Data in children are
limited; a recent article reported the experience with long-term
prophylaxis in pediatric patients, with few patients having an
adequate response (46). Furthermore, antiﬁbrinolytics are not
without adverse effects, most commonly muscle pain and
weakness and/or elevated serum aldolase and creatinine
phosphokinase levels. The requirement for divided daily dosing
may affect adherence.
Finally, fresh frozen plasma (FFP) contains C1-INH and can
be used as prophylaxis prior to dental and surgical procedures.
FFP has also been used as therapy for acute attacks (47).
However, FFP also contains HMWK, and anecdotal reports of
acuteworseningafterFFPwasadministeredduringattackshave
limited its use. The advent of more targeted therapies has
obviated the need for use of FFP in HAE.
Newer therapies
A number of new therapies are now available for the
prevention and treatment of HAE attacks, although experience
in children and adolescents is mostly limited to pC1-INH.
These therapies include C1-INH puriﬁed from plasma (Cin-
ryze
 , ViroPharma Incorporated, Exton, PA; Berinert
 , CSL
Behring GmbH, Marburg, Germany), recombinant C1-INH
(Ruconest
 ; Pharming, Inc; Leiden, The Netherlands), a
kallikrein inhibitor (ecallantide; Kalbitor
 , Dyax Corp, Bur-
lington, MA, USA), and a bradykinin receptor antagonist
(icatibant; Firazyr
 , Shire Human Genetic Therapies, Inc,
Lexington, MA, USA). These options are discussed in the
following text and summarized in the Table 1.
Plasma-puriﬁed C1-INH
C1-INH can be efﬁciently puriﬁed from donated plasma and
used to treat patients with HAE, either prophylactically or to
abort attacks. It is the only targeted therapy for which
substantial pediatric experience has been published.
Berinert has been studied for treatment of acute attacks. It
was effective in alleviating facial and abdominal attacks when
given at a dose of 20 U/kg intravenously (IV), with initial
improvement within a half hour (48,49). Despite its IV
formulation, some patients can either self-administer or have
a caregiver administer this medication, eliminating the need for
a visit to a medical facility for treatment. While originally
approved in the United States for the treatment of abdominal
and facial attacks only (48), it was later approved for the
treatment of laryngeal attacks (49).
Cinryze has been studied for prevention of attacks in a phase
3, double-blind, cross-over trial in patients with severe HAE
(attacks at baseline roughly weekly). Administration of nano-
ﬁltered pC1-INH 1000 units IV twice weekly was associated
with a roughly 50% decline in the number of attacks compared
with placebo. In addition, the severity and duration of attacks
in patients receiving nanoﬁltered pC1-INH were also signif-
icantly decreased (50). An open-label follow-up study showed a
dramatic reduction in attacks in patients receiving pC1-INH
prophylaxis compared with their baseline attack rate. This
study suggested that a small number of patients may do well
with less frequent dosing. Cinryze is approved for prophylaxis
of attacks in adolescents and adults with HAE at the previously
mentioned dose and is also approved for self-administration
(51).
Farkas described the experience with pC1-INH in a cohort
of pediatric patients from Hungary (52). Prior to adulthood, 27
of 50 patients required therapy with pC1-INH (Berinert), for a
total of 152 doses. Therapy was well tolerated, with almost all
attacks responding and initial improvement starting within
60 min in almost all attacks. As seen in adults, a few patients (3
of 50) required frequent treatment, accounting for more than
40% of the total doses given. Similarly, Schneider et al. (53)
described the experience of 15 pediatric patients treated with
pC1-INH (Berinert) during two trials of its efﬁcacy for acute
HAE attacks. The patients were treated for 122 attacks, the
majority receiving open-label therapy. Response to treatment
was rapid, with a median time to improvement of 30 min or
less under both double-blind and open-label conditions.
Finally, Lumry et al. (54) assessed treatment with nanoﬁl-
tered pC1-INH (Cinryze) in 46 pediatric patients. The median
time to onset of improvement of symptoms during acute
attacks in the double-blind phase three study was 30 min,
remarkably similar to the data reported in the other studies
(52,53). Patients given pC1-INH for prophylaxis showed a
decrease in attack rate of nearly 50% in the double-blind study
compared with placebo, and approximately 85% in the open-
label extension compared with historical attacks prior to study
entry (54). Together, these studies indicated that pC1-INH is
safe and effective for treatment of HAE attacks in pediatric
patients and also effective for prophylaxis in appropriate
patients. Of note, most of the children treated in these pediatric
studies were 10 yrs of age or older; a few younger children also
were treated.
Both formulations of pC1-INH are approved in the United
States and Europe for treatment of adolescents and adults
(Berinert is approved in the EU for children as well), with
adolescents being deﬁned as patients 12 yrs of age and older in
the United States. pC1-INH is generally well tolerated,
although the requirement for IV infusion may be a barrier
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Pediatric hereditary angioedema MacGinnitiefor some patients. While pC1-INH is a blood-derived product,
no cases of infection transmitted by C1-INH have been
documented. Likewise, concern about increased thrombosis
risk appears to be theoretical at the doses used for HAE. In
summary, pC1-INH has been demonstrated to be both safe
and effective in pediatric patients with HAE and should be
considered the targeted therapy of choice.
Recombinant C1-INH
The amount of C1-INH that can be puriﬁed from plasma is
limited, and as a blood-derived product, pC1-INH carries a
theoretical risk of infection. An alternative is recombinant
human C1-INH (rC1-INH). rC1INH (Ruconest) is puriﬁed
from the breast milk of transgenic rabbits. Owing to differences
in glycosylation, the half-life of rC1-INH product is signif-
icantly shorter than that of pC1-INH. rC1-INH was found
effective for therapy of acute attacks (55,56), although the
studies were small. Small amounts of leporine protein are
present in the ﬁnal product, so allergy to rabbit is a
contraindication to use (57). It is approved in Europe, but
not the United States, for treatment of acute HAE attacks.
Ecallantide
Ecallantide (Kalbitor) is a potent small peptide kallikrein
inhibitor produced in the yeast Pichia pastoris. It has increased
afﬁnity for kallikrein, compared with C1-INH. Two double-
blind, randomized controlled trials showed that ecallantide,
when administered subcutaneously, was effective in relieving
the symptoms of acute HAE attacks (58,59). Moreover, it
retains efﬁcacy when utilized over time for multiple attacks in
individual patients (60). While generally well tolerated, hyper-
sensitivity reactions, including anaphylaxis, have been
observed in 2.7% of patients treated subcutaneously (61).
MacGinnitie et al. (62) reported the efﬁcacy of ecallantide in 25
pediatric HAE patients treated for a total of 62 attacks, mostly
open label. Ecallantide showed efﬁcacy equivalent to that seen
in adults. Onset of improvement was <1 h, with complete or
near complete resolution of symptoms occurring at a median of
180 min. Ecallantide is approved in the United States, but not
Europe for the treatment of patients with HAE 16 yrs of
age and older, only under the direct supervision of a health-
care professional capable of managing reactions including
anaphylaxis.
Icatibant
Icatibant (Firazyr) is a small peptide containing several
synthetic amino acids that block binding of bradykinin to the
B2 receptor on endothelial cells, decreasing leakage of ﬂuid
across the endothelium and thereby alleviating HAE symp-
toms. Icatibant’s efﬁcacy has been examined in three double-
blind randomized trials for the treatment of acute HAE
attacks, using either placebo or tranexamic acid as a compar-
ator (63,64). Patients showed prompt improvement of symp-
toms, although in one trial, this was not signiﬁcantly better
than comparator, likely because of an unexpectedly rapid
improvement in patients who received placebo. Icatibant is
approved in the United States and Europe for patients age 18
and older. It is given subcutaneously and is easily self-
administered. Patients treated with icatibant often experience
symptoms of pain, burning, and redness at the injection site,
but these are typically manageable (63,64). Icatibant has a
short half-life (approximately 1.5 h), but rebound of symptoms
does not seem to be more prevalent than with other acute
therapies (63–65).
Prophylaxis
The ideal treatment for HAE would completely prevent
attacks, freeing patients to lead a normal life. Although this
has not proven possible in most cases, many patients beneﬁt
from long-term therapy to prevent attacks, and almost all
patients with HAE can use prophylactic medications before
undergoing medical and dental procedures, which commonly
trigger attacks.
Long-term prophylaxis
Three classes of medications can be considered for long-term
prophylaxis: attenuated androgens, antiﬁbrinolytics, and pC1-
INH. Androgens are effective in preventing attacks, but are
associated with signiﬁcant adverse effects, and many patients
require relatively high doses (40). As discussed previously,
androgens should be avoided in children who are still growing.
Antiﬁbrinolytics were formerly the prophylactic treatment of
choice for prepubertal children with HAE, although their
efﬁcacy has not been demonstrated. Currently, C1-INH is the
safest, most effective therapy for long-term prophylaxis in
children and adolescents with HAE and should be considered
thebestoption whenindicated.Cinryze is theC1-INHindicated
for routine prophylaxis in adolescents and adults with HAE.
The decision to undertake long-term prophylaxis is not an
easy one and should be individualized, especially given the cost
of newer HAE medicines. Considerations include the frequency
and severity of attacks; the degree to which HAE disrupts the
patient’s lifestyle, especially work and school; and patient and
family preferences.
Short-term prophylaxis
Short-term prophylaxis is recommended for patients prior to
undergoing invasive procedures that are likely to generate
attacks (5–9). Short courses of androgens are effective in this
role and avoid most of the adverse effects associated with long-
term use (40). C1-INH has also been utilized to good effect in
this role (66). In addition to consideration of prophylaxis, all
patients with HAE should have a plan for treatment if an
attack occurs.
Acute therapy
In the United States, C1-INH is approved for treatment of
adults and adolescents 12 yrs of age and older, while ecallan-
tide is approved for patients age 16 and older and icatibant for
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MacGinnitie Pediatric hereditary angioedemathose 18 and older. C1-INH and icatibant are both approved in
Europe. Because each trial used different end-points to judge
efﬁcacy and no head-to-head trials have been conducted, it is
currently not possible to state that any acute therapy is more or
less efﬁcacious than another. However, there is extensive
experience with pC1-INH as acute therapy in children and
adolescents (52–54), and it represents the current ﬁrst choice
for therapy of attacks in the pediatric population (7,8). It is
hoped that analysis of existing data, combined with that from
new trials, will extend the age range for other acute therapies,
increasing the treatment options for children and adolescents
with HAE.
Conclusions
HAE has been a devastating disease for which few effective
treatment options were available until recently, particularly in
the United States. This has changed dramatically with the
introduction of new therapies for both prevention and treat-
ment of attacks. Because of the risk of severe, life-threatening
attacks, testing is recommended for all at-risk individuals so
that appropriate therapy can be made available. Although
androgens and antiﬁbrinolytics have been used in the past,
pC1-INH is both safe and effective for the prevention of
attacks in the pediatric population. Likewise, extensive data
show that pC1-INH is effective for the treatment of attacks.
Data on the efﬁcacy of other targeted therapies in the pediatric
population are eagerly awaited.
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